United Therapeutics will spend approximately $477.6 million on an accelerated share repurchase, using the remainder of its $2 billion authorization and receiving approximately 719,376 shares initially. For investors, final share delivery will depend on average daily volume-weighted prices, while settlement may involve additional shares, cash, or shares delivered to Citibank.

Key Highlights

  • The initial share delivery will represent approximately 75% of the total shares anticipated under the agreement.
  • United Therapeutics previously repurchased an aggregate $1.5 billion through ASR agreements in March 2026.
  • Final settlement is expected in the fourth quarter of 2026 and may involve additional shares or cash.

The agreement was entered into on September 8, with the upfront payment due on or around September 10 and final settlement expected in the fourth quarter of 2026.

719,376 Shares Delivered Initially

United Therapeutics (NASDAQ: UTHR) will receive approximately 719,376 shares of common stock at the start of the arrangement. The ultimate number of shares will be calculated using the average daily volume-weighted average price during the ASR term, less a discount and subject to contractual adjustments. At settlement, United Therapeutics may receive additional shares, or in limited circumstances pay cash to Citibank or elect to deliver shares.

$2 Billion Authorization Reaches Its Remainder

United Therapeutics previously entered ASR agreements covering an aggregate $1.5 billion of common stock in March 2026. After completing this additional repurchase, the company said it will have returned $4 billion to shareholders in approximately 2.5 years.